The Children’s Hospital of Philadelphia Research Institute | The Children’s Hospital of Philadelphia

3615 Civic Center Boulevard, Philadelphia, PA 19104-4318 215-590-3800

• The University of Pennsylvania
• The Children’s Hospital of Philadelphia

• Event Calendar
• Donate Now
• Subscribe to E-News
• Contact Us
• Research Intranet

• Staff Directory
• Investigator Profiles

• Home /
• Research /
• Investigator Profiles

David T. Teachey

Expertise

CLINICAL:

My clinical interests include pediatric autoimmune disease with emphasis on lymphoproliferative disorders, childhood leukemia, and hematopoietic stem cell transplant.

RESEARCH:

My basic science research focuses on two areas. My first area of interest centers on signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets the mTOR signaling pathway with novel therapeutics and uses xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children. This work has led to a number of nationwide Children's Oncology Group-initiated clinical trials that test mTOR inhibitors in patients with ALL.

The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases. I focus on a rare pediatric disorder called autoimmune lymphoproliferative syndrome (ALPS). Using preclinical models, I am targeting both mTOR and Notch signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases.

My clinical research is focused on better understanding autoimmune diseases in children. I am the principal investigator for a clinical trial that is using the mTOR inhibitor rapamycin in children with multiple medical conditions, including ALPS, chronic ITP, and lupus. I also run an ongoing multi-institutional trial to diagnose and better characterize children with ALPS.

Appointments

Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine (2007 – present)

Education

MD, Medicine, Eastern Virginia Medical School (1999)

B.S, Magna cum laude with Honors in Biology, Virginia Commonwealth University (1993)

Selected Publications

Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. Vol 105(6) . 2005:2443-8.

Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. Vol 108(6) . 2006:1965-71.

Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. Vol 145(1) . 2009:101-6.

Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang Y, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA.. Targeting notch signaling in autoimmune and lymphoproliferative disease.. Blood. Vol 111(2) . 2008:705-14.

Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. Vol 107(3) . 2006:1149-55.

Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. Vol 112(5) . 2008:2020-3.

Teachey DT. Saddle pulmonary embolism as a complication of vasectomy. Urology. Vol 71(2) . 2008:184-5.

Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. Vol 37(1) . 2006:95-9.

Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. Vol 29(8) . 2007:569-73.

Teachey DT. Neonatal MRI and neurodevelopmental outcomes.. N Engl J Med. Vol 355(22) . 2006:2374.

Teachey DT, Grupp SA, and Brown VI. mTOR Inhibitors and their potential role for therapy in leukemia and other haematologic malignancies. Br. J. Haematol.. Vol 145(5) . 2009:569-80.